It’s a well-known fact that a majority of clinical trials fail to meet enrollment deadlines. These delays lead to a significant increase in the cost of bringing a drug to the market. A Clinipace Worldwide study showed that between 2008 and 2011, the cost for a patient in a phase I trial increased 33%, phase II costs rose 75% and phase III costs rose 88%. The smallest increase occurred in phase IV, which still saw costs increase 30%. How can pharmaceutical companies address these seemingly insurmountable clinical trial inefficiencies?
In this article, ZS experts discuss how life sciences companies can improve clinical trials by taking a more holistic, data-driven approach to a trial’s design phase.
- the challenges that pharma companies face when it comes to patient recruitment and enrollment.
- how a data-driven approach can help improve clinical trial design in six key areas.
- how leveraging real-world data with traditional and historical data sources can transform the way that life sciences trials are conducted.